Hiroko Bando

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 12

Top Topics

Reactive Oxygen Species

Top Venues

Breast cancer research and treatment

Journal of medical case reports

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yurina Yanase, Hiroko Bando, Riko Sato, Tomohei Matsuo, Aya Ueda, Mai Okazaki, Sachie Hashimoto, Akiko Iguchi-Manaka, Hisato Hara
Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports. Journal of medical case reports 18 (1) (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment 207 (1) (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment 207 (1) (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment 207 (1) (2024)
Toshimi Takano, Norikazu Masuda, Mitsuya Ito, Kenichi Inoue, Yuko Tanabe, Kousuke Kawaguchi, Hiroyuki Yasojima, Hiroko Bando, Rikiya Nakamura, Takashi Yamanaka, Kazushige Ishida, Tomoyuki Aruga, Yasuhiro Yanagita, Eriko Tokunaga, Kenjiro Aogi, Shinji Ohno, Hiroi Kasai, Tatsuki R Kataoka, Satoshi Morita, Masakazu Toi
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks). Breast cancer research and treatment 207 (1) (2024)
Yurina Yanase, Hiroko Bando, Riko Sato, Tomohei Matsuo, Aya Ueda, Mai Okazaki, Sachie Hashimoto, Akiko Iguchi-Manaka, Hisato Hara
Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports. Journal of medical case reports 18 (1) (2024)
Yurina Yanase, Hiroko Bando, Riko Sato, Tomohei Matsuo, Aya Ueda, Mai Okazaki, Sachie Hashimoto, Akiko Iguchi-Manaka, Hisato Hara
Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports. Journal of medical case reports 18 (1) (2024)
Keiko Inoue, Noriko Iida, Kazuko Tajiri, Hiroko Bando, Shigeru Chiba, Nobutaka Tasaka, Kenji Nagashio, Rumi Sasamura, Hiroyuki Naito, Momoko Murata, Siqi Li, Tomoko Ishizu, Yoko Nakazawa, Ikuo Sekine, Masaki Ieda
Rationale, Design, and Feasibility of a Prospective Multicenter Registry Study of Anthracycline-Induced Cardiotoxicity (AIC Registry). Journal of clinical medicine 10 (7) (2021)
Eriko Tokunaga, Norikazu Masuda, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando, Tomoyuki Aruga, Shoichiro Ohtani, Tomomi Fujisawa, Toshimi Takano, Kenichi Inoue, Nobuyasu Suganuma, Masahiro Takada, Kenjiro Aogi, Kenichi Sakurai, Hideo Shigematsu, Katsumasa Kuroi, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). Cancers 13 (16) (2021)
Azusa Terasaki, Hiromi Kurokawa, Hiromu Ito, Yoshiki Komatsu, Daisuke Matano, Masahiko Terasaki, Hiroko Bando, Hisato Hara, Hirofumi Matsui
Elevated Production of Mitochondrial Reactive Oxygen Species via Hyperthermia Enhanced Cytotoxic Effect of Doxorubicin in Human Breast Cancer Cell Lines MDA-MB-453 and MCF-7. International journal of molecular sciences 21 (24) (2020)
Sachie Hashimoto, Emiko Noguchi, Hiroko Bando, Hiroko Miyadera, Wataru Morii, Takako Nakamura, Hisato Hara
Neoantigen prediction in human breast cancer using RNA sequencing data. Cancer science 112 (1) (2020)